title: The effects of SB 206284A, a novel neuronal calcium-channel antagonist, in models of cerebral ischemia.
abstract: The effects of SB 206284A, 1-[7-(4-benzyloxyphenoxy)heptyl] piperidine hydrochloride, have been investigated in vitro on calcium and sodium currents in rat-cultured dorsal root ganglion (DRG) neurones and potassium-mediated calcium influx in rat synaptosomes. Cardiovascular hemodynamic effects in both anesthetized and conscious rats, and neuroprotective activity in in vivo cerebral ischemia models were also investigated. In the rat DRG cells, SB 206284A caused almost complete block of the sustained inward Ca2+ current (IC50 = 2.4 microM), suggesting that the compound is an effective blocker of slowly inactivating, high-voltage calcium current. SB 206284A reduced locomotor hyperactivity in the gerbil bilateral carotid artery occlusion model without affecting ischemia-induced damage in the hippocampal CA1 region. In the rat middle cerebral artery occlusion model, SB 206284A reduced lesion volume in the posterior forebrain, and in the rat photochemical cortical lesion model, lesion volume was reduced even when treatment was delayed until 4 hours after occlusion. At neuroprotective doses, SB 206284A had no cardiovascular effects. These findings show that SB 206284A is a novel calcium channel antagonist that shows neuroprotective properties.
authors.affiliation: SmithKline Beecham Pharmaceuticals, Harlow, Essex, United Kingdom.
authors.forename: N I
authors.initials: NI
authors.lastname: Wood
authors.forename: F C
authors.initials: FC
authors.lastname: Barone
authors.forename: C D
authors.initials: CD
authors.lastname: Benham
authors.forename: T H
authors.initials: TH
authors.lastname: Brown
authors.forename: C A
authors.initials: CA
authors.lastname: Campbell
authors.forename: D G
authors.initials: DG
authors.lastname: Cooper
authors.forename: M L
authors.initials: ML
authors.lastname: Evans
authors.forename: G Z
authors.initials: GZ
authors.lastname: Feuerstein
authors.forename: T C
authors.initials: TC
authors.lastname: Hamilton
authors.forename: M H
authors.initials: MH
authors.lastname: Harries
authors.forename: P D
authors.initials: PD
authors.lastname: King
authors.forename: J E
authors.initials: JE
authors.lastname: Meakin
authors.forename: K L
authors.initials: KL
authors.lastname: Murkitt
authors.forename: S R
authors.initials: SR
authors.lastname: Patel
authors.forename: W J
authors.initials: WJ
authors.lastname: Price
authors.forename: J C
authors.initials: JC
authors.lastname: Roberts
authors.forename: A L
authors.initials: AL
authors.lastname: Rothaul
authors.forename: N A
authors.initials: NA
authors.lastname: Samson
authors.forename: S J
authors.initials: SJ
authors.lastname: Smith
authors.forename: A J
authors.initials: AJ
authors.lastname: Hunter
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects / Q000473:pathology; D002545:Brain Ischemia / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D015220:Calcium Channels / Q000378:metabolism*; D002144:Callithrix; D002319:Cardiovascular System / Q000187:drug effects; D004594:Electrophysiology; D005727:Ganglia, Spinal / Q000187:drug effects / Q000502:physiology; D005849:Gerbillinae; D008297:Male; D009474:Neurons / Q000378:metabolism*; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D017207:Rats, Sprague-Dawley; D013574:Synaptosomes / Q000378:metabolism
chemical_list: D002121:Calcium Channel Blockers; D015220:Calcium Channels; D018696:Neuroprotective Agents; D010880:Piperidines; C105906:SB 206284A; D002118:Calcium